Therapure Biopharma Inc Contract Manufacturing Agreement [Member]
Therapure
Represents the agreement with Therapure Biopharma Inc., for manufacture of the entity product ARIKAYCE, liposomal amikacin for inhalation.
Initial term of contract manufacturing agreement
Represents the initial period of contract manufacturing agreement.
Initial Term of Contract Manufacturing Agreement
Period of Each Automatic Renewal of Contract Manufacturing Agreement
Period of each automatic renewal of contract manufacturing agreement
Represents the period of each automatic renewal of contract manufacturing agreement.
Written Notice Period for Termination of Contract Manufacturing Agreement
Written notice period required for termination of contract manufacturing agreement
Represents the written notice period required for termination of contract manufacturing agreement by either party.
Advance Notice Period for Termination of Contract Manufacturing Agreement by the Entity
Advance notice period for termination of contract manufacturing agreement by the entity
Represents the advance notice period for termination of contract manufacturing agreement by the entity.
Contract Manufacturing Agreement [Member]
Agreement with Therapure Biopharma Inc.
Represents information pertaining to contract manufacturing agreement entered for the manufacture of the Company's product ARIKAYCE.
Reclass of stock compensation expense for liability awards to equity
Represents the amount of reclass of equity-based compensation for liability awards to equity during the period.
Adjustments to Additional Paid in Capital Share based Compensation for Liability Awards
The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are non-vested as of the balance sheet date.
Share Based Compensation Arrangement by Share Based Payment Award Options Outstanding Nonvested Number
Non-vested
Represents the agreement with Cystic Fibrosis Foundation Therapeutics, Inc., for research funding for the development of ARIKAYCE product.
Cystic Fibrosis Foundation Therapeutics Inc Collaboration Agreements [Member]
CFFT
Tri Act Therapeutics Inc License Agreement [Member]
TriAct License Agreement
Represents the agreement with TriAct Therapeutics Inc, whereby it granted counter party an exclusive license for INS-18.
Amendment Description
Number of shares received
Represents number of shares received under the collaborative arrangements.
Collaborative Arrangements and Noncollaborative Arrangement Transactions Number of Shares Received
Amendment Flag
Manufacturing Equipment [Member]
Manufacturing Equipment
Represents manufacturing equipment used to produce goods and services.
Property, Plant and Equipment used in Manufacturing Process Located at Contract Manufacturer
Fixed assets used in the manufacturing process is located at contract manufacturer
Represents certain owned fixed assets used in the manufacturing process is located at contract manufacturer.
Unrecognized Tax Benefits Reserves
Unrecognized tax benefits, reserves
Represents the amount of reserves for unrecognized income tax benefits as of the date.
Monmouth Junction New Jersey Facility [Member]
Monmouth Junction New Jersey Facility
Represent the Monmouth Junction location in New Jersey where the entity has leased office and laboratory space.
Bridgewater New Jersey Facility [Member]
Bridgewater New Jersey Facility
Represent the Bridgewater location in New Jersey where the entity has leased office and laboratory space.
Effective Income Tax Rate Reconciliation Permanent Items
Permanent items (as a percent)
The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to permanent items.
Issuance of Preferred Stock upon Merger in Shares
Issuance of preferred stock upon merger (in shares)
Value of preferred stock issued pursuant to acquisitions during the period.
Issuance of Common Stock for Warrant Exercises
Exercise of warrants (in shares)
Shares of stock issued during the period as a result of the exercise of stock warrants.
Value of stock issued during the period as a result of the exercise of stock warrants.
Stock Issued During Period Value Warrants Exercised
Exercise of warrants
Stock Issued During Period Value Merger Common Stock
Issuance of common stock upon merger
Represents the value of common stock issued during the period for a merger.
Represents the number of shares of common stock issued during the period for a merger.
Stock Issued During Period Shares Merger Common Stock
Issuance of common stock upon merger (in shares)
Stockholders Equity Note Stock Split Adjustment
1 for 10 reverse stock split
Represents the adjustment to equity as a result of a reverse stock split.
Document and Entity Information
Other Accrued Liabilities Disclosure [Text Block]
Accrued Expenses
Disclosure of accrued liabilities, excluding liabilities related to accrued lease expense and accrued compensation.
Collaboration Agreements
Exercise of Buyout Option
Beneficial Conversion Charge ("BCC")
Beneficial Conversion Charge ("BCC")
Current Fiscal Year End Date
Award Type [Axis]
Minimum Percentage of Likelihood for Recognition of Tax Benefits
Represents the minimum percentage of likelihood for recognition of tax benefits.
Minimum percentage of likelihood for recognition of tax benefits (in hundredths)
License and Collaborative Agreements [Text Block]
Collaboration Agreements
This entire text block refers to License and Collaborative Agreement.
Investment Income (Expense) [Policy Text Block]
Investment Income and Interest Expense
Disclosure of accounting policy for components of investment income and interest expense.
Common Stock Reverse Split
Disclosure of accounting policy for the common stock reverse split in conformity with generally accepted accounting principles.
Common Stock Reverse Split [Policy Text Block]
Beneficial Conversion Charge [Policy Text Block]
Beneficial Conversion Charge ("BCC")
Disclosure of accounting policy for beneficial conversion charge. This accounting policy address how an entity issuing debt or equity securities that are convertible into common stock at a discount from the fair value of the common stock at the date the debt or equity financing is committed.
Accrued Clinical Trial Expenses
Accrued clinical trial expenses
Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.
Liability for Stock Based Compensation Awards
Liability for stock-based compensation awards
Liability accrued for stock based compensation awards as of the report date.
One of two secured promissory notes included in the loan agreement.
Note A [Member]
Note A
Note B [Member]
Note B
One of two secured promissory notes included in the loan agreement.
Note A and Note B [Member]
Notes
Represents information pertaining to the Note A and Note B, secured promissory notes included in the loan agreement.
Incremental Amount of Term Loan
Incremental amount of term loan
The increments of Company borrowings by signing two Secured Promissory Notes ("Note A and B").
Document Period End Date
Maximum amount of the subsequent private financing of equity securities pursuant to the Loan Agreement, which the lender has the right to participate in.
Maximum Amount of Subsequent Private Financing of Equity Securities
Limit on lender's participation rights in certain future private equity financings
Number of Secured Promissory Notes
Number of Secured Promissory Notes
The number of Secured Promissory Notes execute to secure the Company borrowings.
Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.
Debt Instrument, Payment Periods
Period over which note is to be repaid
Number of Payment Periods Representing Interest Only
Payment periods representing interest only
Number of the first monthly payment periods representing interest only.
Periods of equal payment of principal and interest
Number of payment periods of equal payments of principal and interest.
Number of Payment Periods of Equal Payments of Principal and Interest
Represents the period over which principal payment of notes under loan agreement could be delayed.
Debt Instrument, Periods over which Principal Payment Could be Delayed
Period over which principal payment could be delayed
End of Term Charge
"End of term" charge
The cost incurring from "end of term" charge to the Loan Agreement. This expense is being charged to interest expense using the effective interest method over the life of the Loan Agreement.
Additional Interest Rate to Outstanding Loan Balances
Additional interest rate in event of default (as a percent)
Represents an additional interest rate charge to outstanding loan balances in event of a default.
Add [Abstract]
Add:
Less [Abstract]
Less:
Accretion of end of term charge
Represents the cumulative amount of the end of term charge which has been accreted as of the balance sheet date.
Additional Charge at End of Term
Unamortized Discount from Warrant
Discount from warrant
Unamortized discount from the issuance of warrants as of the report date.
Arrangements and Non-arrangement Transactions [Domain]
Premacure License Agreement [Member]
Premacure License Agreement
Represents the agreement with Premacure Holdings AB and Premacure AB of Sweden pursuant to which the reporting entity granted an exclusive worldwide license to develop manufacture and commercialize IGH-1, with its natural binding protein, IGFBP-3, for the prevention and treatment of complications of preterm birth.
Option Price for License
License purchase option price
Represents the option provided to the licensee to purchase a fully paid option for cash payment.
Proceeds from Sale of License
Proceeds from sale of license
Represents the amount received by the entity in sale of a fully paid license related to the entity's product(s).
Royalty Payment Period
Royalty payment period
Period for royalty payments under a research and development agreement.
Period for Meeting Sales Milestones for Additional Royalty Payments
Period for meeting sales milestones for additional royalty payments
Period for meeting sales milestones for additional royalty payments after the drug is commercialized.
Additional Royalty Guarantees Commitments Amount
Royalty payable on meeting certain sales milestones
Amount of royalty payments if entity meets certain milestones under a research and development agreement.
Complete disclosure of the company's beneficial conversion charge related to debt and equity securities.
Beneficial Conversion Charge [Text Block]
Beneficial Conversion Charge ("BCC")
Computer Hardware and Software [Member]
Computer hardware and software
Purchased computer hardware and software applications.
Amended and Restated 2000 Stock Incentive Plan [Member]
Represents the Amended and Restated 2000 Stock Incentive Plan.
Previous equity compensation plan
Incentive Plan, 2013 [Member]
Represents the 2013 Incentive Plan.
2013 Incentive Plan
Share Based Compensation Arrangement by Share Based Payment Award, Right to Purchase Maximum Value of Shares
Value of shares that can be purchased under the plan per year
The maximum value which each eligible employee can purchase under the plan per year.
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life in Years [Abstract]
Range 1 [Member]
$3.03 to $3.29
Selected disclosure of Stock options outstanding and exercisable by share price exercise range.
Range 2 [Member]
$3.40 to $3.40
Selected disclosure of Stock options outstanding and exercisable by share price exercise range.
Range 3 [Member]
$3.48 to $6.90
Selected disclosure of Stock options outstanding and exercisable by share price exercise range.
Range 4 [Member]
$6.96 to $10.35
Selected disclosure of Stock options outstanding and exercisable by share price exercise range.
Range 5 [Member]
$11.14 to $11.46
Selected disclosure of Stock options outstanding and exercisable by share price exercise range.
Range 6 [Member]
$12.44 to $12.44
Selected disclosure of Stock options outstanding and exercisable by share price exercise range.
Range 7 [Member]
$12.58 to $12.58
Selected disclosure of Stock options outstanding and exercisable by share price exercise range.
Range 8 [Member]
$12.70 to $15.61
Selected disclosure of Stock options outstanding and exercisable by share price exercise range.
Range 9 [Member]
$15.63 to $20.49
Selected disclosure of Stock options outstanding and exercisable by share price exercise range.
Range 10 [Member]
$21.54 to $21.54
Selected disclosure of Stock options outstanding and exercisable by share price exercise range.
Restricted Stock and Restricted Stock Units [Member]
Restricted Stock and Restricted Stock Units
Shares and stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.
Number of Common Shares to be Received in Lieu of Per Rs and Rsu
Number of common shares each award holder is entitled to receive
Number of shares of common stock each restricted stock award entitles the holder to receive upon completion of a specific period of service or achievement of a specified milestone.
Share Based Compensation Arrangement by Share Based Payment Award other than Options Vested and Expected to Vest Outstanding Number
Expected to Vest (in shares)
As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the other than option plan.
Expected to Vest (in dollars per share)
Weighted average grant price of other than options instruments expected to vest.
Weighted Average Grant Price Expected to Vest
Share Based Compensation Arrangement by Share Based Payment Award, Awards in Excess of Maximum Number of Shares Allowed Per Employee
RSUs and stock options in excess of the per person annual sub-limits
Represents the number of share based compensation awards which exceeded the maximum number of awards allowable per employee.
Number of Leases
Number of Leases
Number of operating leases for office and laboratory space located in Monmouth Junction, NJ.
New Jersey Facility
Represent the location in New Jersey where the entity has leased office and laboratory space.
New Jersey Facility [Member]
Represent the location in Virginia where the entity's previous corporate headquarters were located.
Richmond Facility [Member]
Richmond facility
Lease Termination Charge
Net present value charge
Represents the present value of lease recorded due to vacating the premises.
Cachillo V Insmed [Member]
Cacchillo v. Insmed
Represents complaint filed against the reposting entity by Angeline Cacchillo seeking monetary damages and a court order requiring the entity to support a compassionate use application to the FDA.
Pikliewicz V Transave LLC [Member]
Pilkiewicz v. Transave LLC
Represents an appraisal action challenging the valuation that plaintiffs would have received in merger transaction.
Number of Shares under Appraisal of Combined Common Stock Holdings
Number of dissenting shares to Transave Merger represented in appraisal action
Number of shares requesting appraisal.
Total Holdback Shares as Securities for Indemnification Payments due under Merger Agreement in Shares
Total holdback shares as securities for indemnification payments due under merger agreement
Number of shares withheld by the company as security for its indemnification of liabilities in accordance with the merger agreement.
Operating Loss Carryforwards Sold
State NOLs sold under the State of New Jersey's Technology Business Tax Certificate Transfer Program
The sum of net operating loss carryforwards sold by the reporting entity.
Proceeds from Sale of NOL, Net
Cash proceeds from sale of NOLs, net of commissions
Represents the cash inflow received from the sale of net operating loss carryforwards, net of commissions.
Proceeds from the sale of certain net operating losses related to prior years
Increase in Ownership of Certain Shareholders or Public Group
Ownership change, as defined in Section 382, which could limit utilization of NOLs (as a percent)
Represent the percentage of change in ownership which could result over a specified period that could result in a limitation on the use of NOLs.
Period of Increase in Ownership of Certain Shareholders or Public Groups
Period of time for measuring ownership changes under Section 382
Represent the period of time in which ownership changes are measured for purposes of applying Section 382 to limit utilization of NOLs.
Expired net operating loss carryforwards (as a percent)
The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to net operating loss carryforwards.
Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforwards
Effective Income Tax Rate Reconciliation Alternative Minimum Tax
Alternative minimum tax (as a percent)
The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to alternative minimum tax.
Entity Well-known Seasoned Issuer
Deferred Tax Liabilities in Process Research and Development
In-process research and development
Amount of deferred tax liability attributable to in-process research and development.
Entity Voluntary Filers
Net deferred tax assets
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.
Deferred Tax Assets (Liabilities) Net before Valuation Allowances
Entity Current Reporting Status
Number of equity compensation plans.
Number of Equity Compensation Plans
Number of equity compensation plans
Entity Filer Category
Amount of a favorable spread to an equity instrument holder between the amount of stock being converted and the value of the securities received upon conversion.
Equity Instrument Convertible Beneficial Conversion Feature
Accretion of beneficial conversion charge
Entity Public Float
The net change in fair value of warrants in connection with debt during the reporting period.
Fair Value of Warrants in Connection with Debt
Value of warrant exercised by converting the warrant into shares of common stock ("net issuance method")
Entity Registrant Name
The increase (decrease) during the reporting period in the sum of accrued expenses and the deferred rent credit.
Increase (Decrease) in Accrued Liabilities and Deferred Rent Credit
Accrued expenses and deferred rent
Entity Central Index Key
Increase (Decrease) in Accrued Lease Expenses
Accrued lease expenses
The increase (decrease) in accrued lease expenses not included in the increase (decrease) in other accrued liabilities and deferred rent credit.
Stock Issued During Period Value Acquisitions Preferred Stock
Issuance of preferred stock upon merger
Value of preferred stock issued pursuant to acquisitions during the period.
Class of Warrant or Right Expiration Term
Expiration term
The period of time, from the grant date until the time at which the warrant expires.
Number of initial indications in orphan patient populations for which clinical trials of ARIKAYCE is conducted
Represents the number of initial indications in orphan patient populations for which clinical trials are conducted by the entity.
Number of Initial Indications in Orphan Patient Populations for which Clinical Trials Conducted
Entity Common Stock, Shares Outstanding
Period of extension study for Phase 3 clinical trial in cystic fibrosis ("CF") patients
Represents the period of extension study in clinical trial conducted by the entity.
Clinical Trial Extended Study Period
Open Label Safety Study Period
Open-label safety study period
Represents the period of open-label safety study that is enrolling eligible patients who have completed the entity's Phase 3 registrational clinical trial in CF patients.
Represents the number of entities integrated.
Number of entities integrated
Number of Entities Integrated
Represents information pertaining to equipment, furniture and fixtures.
Equipment, Furniture and Fixtures [Member]
Computer equipment, laboratory equipment, office equipment and furniture and fixtures
Number of Shares Held by Entity Stockholders after Conversion Adjustment
Number of shares held by entity stockholders after conversion adjustment (in shares)
Represents the number of shares held by entity's stockholders after the conversion adjustment.
Mutual Funds [Member]
A mutual fund is a type of professionally managed collective investment vehicle that pools money from many investors to purchase securities.
Mutual Funds
Carrying Value Per Share
Carrying value per share.
Carrying value per share (in dollars per share)
Non cash charge for beneficial conversion (in dollars per share)
Non Cash Charge for Beneficial Conversion
Non-cash charge for beneficial conversion.
Conversion Price Per Share
Conversion price per share.
Conversion price per share (in dollars per share)
License price due
Represents the license price due upon exercise of buyout option.
License Price Due
Represents the number of each class of warrants or rights issued at a specific price, on or before a certain date.
Class of Warrant or Right Issued
Warrant Shares issued and delivered
Common Stock Shares Exercise to Underwriters in Full of over Allotment Option
Number of share's exercise in full of over-allotment option by underwriter
Represents the number of share's exercise in full of over-allotment option by underwriter.
Share Price for Underwriter
Purchase price of shares for underwriter (in dollars per share)
Represents the purchase price for the underwriter for a single share of a number of saleable stocks of a company.
The remaining number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan that are transferred from one plan to another during the reporting period.
Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Inter Plan Transfers
Number of shares transferred from previous plan
Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Vesting on First Anniversary
Number of the shares vesting on first anniversary
Represents the number of shares vesting on the first anniversary.
Represents the number of shares vesting from the first anniversary through the fourth anniversary.
Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Vesting from First Anniversary Through Fourth Anniversary
Number of the shares vesting from first anniversary through fourth anniversary
Share Based Compensation Arrangement by Share Based Payment, Number of Equal Installments Following First Anniversary Date Through Fourth Anniversary
Number of equal installments following the first anniversary date through the fourth anniversary
Represents the number of equal installments vested following the first anniversary date through the fourth anniversary of the date of grant, subject to continued employment with the entity during the reporting period.
Document Fiscal Year Focus
Number of stock options vest on the date of the company's issuance of quarterly earnings (in shares)
Represents the number of stock options vesting on the date of the entity's issuance of quarterly earnings release pertaining to the fiscal quarter during the reporting period.
Share Based Compensation Arrangement by Share Based Payment, Number of Stock Options Vesting on Date of Issuance of Quarterly Earnings
Document Fiscal Period Focus
Represents the number of shares vested in equal installments vested following the First Anniversary Date through the fourth anniversary of the date of grant, subject to continued employment with the entity during the reporting period.
Share Based Compensation Arrangement by Share Based Payment, Number of Shares Vested in Equal Installments Following First Anniversary Date Through Fourth Anniversary
Number of shares vested in equal installments following the First Anniversary Date through the fourth anniversary
Represents the number of outstanding stock options deemed to be granted outside the entity's incentive plans as of the balance sheet date.
Share Based Compensation Arrangement by Share Based Payment Award, Outstanding Options Deemed to be Granted Outside Incentive Plans
Number of outstanding stock options deemed to be granted outside the Company's incentive plans (in shares)
Amount of cumulative revenues from all approved products
Represents the amount of cumulative revenues from all approved products subject to continued employment with the entity through such date.
Share Based Compensation Arrangement by Share Based Payment, Amount of Required Cumulative Revenues from All Approved Products
Period of equal installments
Represents the period of equal installments vested following the First Anniversary Date through the fourth anniversary of the date of grant, subject to continued employment with the entity during the reporting period.
Share Based Compensation Arrangement by Share Based Payment, Period of Equal Installment
Stock-based compensation expense that resulted from the remeasurement of awards
Represents the amount of stock-based compensation expense that resulted from the remeasurement of awards.
Allocated Share Based Compensation Expense, Due to Remeasurement of Awards
Represents the number of patients enrolled in clinical trials conducted by the entity.
Number of Patients Enrolled in Clinical Trials Conducted
Number of patients enrolled in clinical trials of ARIKAYCE
Accrued clinical trial and manufacturing expenses
Carrying value, as of the balance sheet date, of obligations incurred through that date and payable for clinical trial expenses and manufacturing expenses.
Accrued Clinical Trial Expenses and Manufacturing Expenses Current
Value of stock issued during the period as a result of warrants granted in connection with debt financing.
Stock Issued During Period Value Warrants Granted in Connection with Debt
Fair value of warrants granted in connection with debt financing
Issuance of Common Stock for Warrant Granted in Connection with Debt
Fair value of warrants granted in connection with debt financing (in shares)
Shares of stock issued during the period as a result of warrants granted in connection with debt financing.
Accrued Contract Manufacturer Expenses Current
Contract Manufacturer expenses
Liability accrued for contract manufacturer expenses as of the report date.
Ipsen and Genentech License Agreement [Member]
Ipsen and Genentech License Agreement
Represents the agreement with Ipsen and Genentech to develop IPLEX in certain medical indications in the US and foreign territories.
Eleison Pharmaceuticals License Agreement [Member]
Eleison License Agreement
Represents the agreement with Eleison Pharmaceuticals, whereby it granted counter party an exclusive license for CISPLATIN Lipid Complex.
Document Type
Debt Instrument Fee Paid to Extend Interest only Period
Fee paid to extend the interest-only period
Represents the fee to be paid which would allow the entity to extend the interest-only payment period.
Summary of Significant Accounting Policies
Stock options and RSUs
Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.
Stock Options and Restricted Stock Units [Member]
The portion of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the state tax rates.
Effective Income Tax Rate Reconciliation Change in State Tax Rate
Change in state tax rate (as a percent)
Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.
Accrued Technical Operation Expenses
Accrued technical operation expenses
Collaborative Arrangement Initial Term
Initial term of collaborative arrangement
Represents the term of the collaborative agreement.
Represents the successive renewal period of the collaborative agreement.
Collaborative Arrangement Successive Renewal Period
Successive renewal period of collaborative arrangement
Collaborative Arrangement Prior Written Notice Period for Termination by Either Party
Prior written notice period for termination
Represents the prior written notice period required for termination of agreement by either party.
Collaborative Arrangement Minimum Number of Days of Advance Notice for Termination
Minimum number of days of advance notice for termination
Represents the minimum number of advance notice required for termination of agreement by the entity.
Stock options
Stock options to purchase common stock
Employee and Directors Stock Options [Member]
An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.
Fair Value of Warrants Outstanding
Value of warrant exercised by converting the warrant into shares of common stock ("net issuance method")
Represents the amount of change in value of warrant exercised by converting the warrant into shares of common stock.
PARI Pharma GmbH Commercialization Agreement [Member]
PARI Agreement
Represents the agreement with PARI Pharma GmbH, for the manufacture and supply of eFlow nebulizer systems and related accessories, liposomal amikacin for inhalation.
Additional Term of Contract Manufacturing Agreement
Additional term of contract manufacturing agreement
Represents the additional extension period of contract manufacturing agreement.
Accounts receivable
Accounts Receivable, Net, Current
Accounts payable
Accounts Payable, Current
Accrual of the end of term charge on the debt
Accretion Expense
Accrued Expenses
Accrued lease expense, long-term
Accrued Rent, Noncurrent
Remaining rental accrual
Accrued Rent
Total accrued expenses
Accrued expenses
Accrued Liabilities, Current
Accrued lease expense, current
Accrued Rent, Current
Accrued professional fees
Accrued Professional Fees, Current
Less accumulated depreciation and amortization
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Unrealized gain on investments, net of taxes
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated other comprehensive income:
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Additional paid-in capital
Additional Paid in Capital
Additional Paid-in Capital
Additional Paid-in Capital [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Stock compensation expense
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition
Allocated share-based compensation expense
Allocated Share-based Compensation Expense
Amortization of debt discount and debt issuance costs
Amortization of Financing Costs and Discounts
Antidilutive Securities [Axis]
Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities, Name [Domain]
Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Impairment loss
Non-cash impairment loss
Asset Impairment Charges
Total assets
Assets
Current assets:
Assets, Current [Abstract]
Assets
Assets [Abstract]
Total current assets
Assets, Current
Total assets measured at fair value
Assets, Fair Value Disclosure
Fair Value of securities in an unrealized loss position
Securities that were in an unrealized loss or gain position
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
Amortized Cost
Available-for-sale Securities, Amortized Cost Basis
Business Acquisition, Equity Interests Issued or Issuable
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Holdback shares retained as security for indemnification payments
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares
Capital lease obligations, current
Capital Lease Obligations, Current
Net carrying value of capital lease obligations
Capital Lease Obligations
Capital lease obligations, long-term
Capital Lease Obligations, Noncurrent
Capital lease obligations incurred
Capital Lease Obligations Incurred
Decrease in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Cash and Cash Equivalents, at Carrying Value
Cash and Cash Equivalents
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Supplemental disclosures of non-cash investing and financing activities:
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Certificate of deposit
Certificates of Deposit, at Carrying Value
Warrant Shares outstanding
Class of Warrant or Right, Outstanding
Common stock disclosures
Class of Stock [Line Items]
Warrant to purchase common stock, number of shares
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Exercise price of warrants (in dollars per share)
Class of Warrant or Right, Exercise Price of Warrants or Rights
License and Collaborative Agreements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Commitments and Contingencies
Commitments and contingencies
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Common stock, par value (in dollars per share)
Common Stock, Par or Stated Value Per Share
Common Stock
Common Stock [Member]
Common stock, $0.01 par value; 500,000,000 authorized shares, 39,276,389 and 39,137,679 issued and outstanding shares at June 30, 2014 and December 31, 2013, respectively.
Common Stock, Value, Issued
Common stock, issued shares
Common Stock, Shares, Issued
Common stock, authorized shares
Common Stock, Shares Authorized
Common stock shares reserved for issuance
Common Stock, Capital Shares Reserved for Future Issuance
Common stock, outstanding shares
Common Stock, Shares, Outstanding
Retirement Plan
Deferred tax assets
Components of Deferred Tax Assets [Abstract]
Deferred tax assets and liabilities
Components of Deferred Tax Assets and Liabilities [Abstract]
Deferred tax liabilities
Components of Deferred Tax Liabilities [Abstract]
Comprehensive loss:
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Comprehensive (Loss) Income
Comprehensive Income, Policy [Policy Text Block]
Comprehensive loss attributable to commonstockholders
Total comprehensive loss
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Net loss and comprehensive loss
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentration of Credit Risk
Principles of Consolidation
Consolidation, Policy [Policy Text Block]
Construction in Progress (CIP)
Construction in Progress [Member]
Conversion of preferred stock into common stock (in shares)
Conversion of Stock, Shares Issued
Conversion of Series B preferred stock into common stock
Equivalent amount in conversion of preferred stock to common stock
Conversion of Stock, Amount Converted
Conversion of preferred stock into common stock
Conversion of Stock, Amount Issued
Components of the Company's debt balance
Debt, Long-term and Short-term, Combined Amount [Abstract]
Variable interest rate in event of default (as a percent)
Debt Instrument, Description of Variable Rate Basis
Debt
Debt Instrument [Line Items]
Schedule of Long-term Debt Instruments [Table]
Non-cash BCC recorded
Debt Instrument, Convertible, Beneficial Conversion Feature
Debt
Debt
Debt Disclosure [Text Block]
Debt Instrument [Axis]
Discount on fair value of common stock (in dollars per share)
Debt Instrument, Convertible, Conversion Price
Debt Instrument, Name [Domain]
Debt Issuance Costs
Debt, Policy [Policy Text Block]
Current portion of long-term debt
Debt, Current
Interest rate (as a percent)
Debt Instrument, Interest Rate, Stated Percentage
Debt:
Debt Instruments [Abstract]
Deferred Offering Costs
Deferred Charges, Policy [Policy Text Block]
Deferred tax liabilities
Deferred Tax Liabilities, Gross
Net deferred tax assets
Deferred Tax Assets, Net
Deferred revenue
Deferred rent
Deferred Rent Credit, Current
Gross deferred tax assets
Deferred Tax Assets, Gross
Other
Deferred Tax Assets, Other
General business credits
Deferred Tax Assets, Tax Credit Carryforwards, General Business
Net operating loss carryforwards
Deferred Tax Assets, Operating Loss Carryforwards
Alternative Minimum Tax (AMT) credit
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax
Valuation allowance
Deferred Tax Assets, Valuation Allowance
Other
Deferred Tax Liabilities, Other
Employer contribution to retirement plan
Defined Contribution Plan, Employer Discretionary Contribution Amount
Retirement Plan
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]
Deposits
Depreciation expense
Depreciation
Depreciation and amortization
Depreciation, Depletion and Amortization
Effect of dilutive securities:
Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]
Stock-Based Compensation
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Net loss per share:
Earnings Per Share, Basic and Diluted [Abstract]
Basic and diluted net loss per share (in dollars per share)
Basic and Diluted (in dollars per share)
Earnings Per Share, Basic and Diluted
Net Loss Per Common Share
Earnings Per Share, Policy [Policy Text Block]
Diluted net (loss) income attributable to common stockholders per common share (in dollars per share)
Net Loss Per Common Share
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Effective tax rate (as a percent)
Effective tax rate (as a percent)
Effective Income Tax Rate Reconciliation, Percent
Research and development credit (as a percent)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Differences between the U.S. federal statutory tax rate and effective tax rate
Effective Income Tax Rate Reconciliation, Percent [Abstract]
State income taxes net of federal benefit (as a percent)
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
Other (as a percent)
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Change in valuation allowance (as a percent)
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Statutory federal tax rate (as a percent)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
Accrued compensation
Employee-related Liabilities, Current
Stock Purchase Plan
Employee Stock [Member]
Unrecognized compensation expense related to unvested RSU's
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options
Expected weighted average period for recognizing unrecognized compensation expense
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition
Unrecognized compensation expense related to unvested stock options
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options
Lab equipment
Equipment [Member]
Equity Interest Type [Axis]
Equity interest of Transave stockholders (in hundredths)
Equity Method Investment, Ownership Percentage
Equity Interest Issued or Issuable, Type [Domain]
Equity Component [Domain]
Measurement Frequency [Axis]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Hierarchy [Axis]
Recurring basis
Fair Value, Measurements, Recurring [Member]
Transfer of assets from Level 2 into Level 1
Fair Value, Assets, Level 2 to Level 1 Transfers, Amount
Fair Value, Measurement Frequency [Domain]
Assets measured at fair value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Hierarchy [Domain]
Fair Value Measurements
Fair Value of Financial Instruments, Policy [Policy Text Block]
Level 3
Fair Value, Inputs, Level 3 [Member]
Level 1
Fair Value, Inputs, Level 1 [Member]
Level 2
Fair Value, Inputs, Level 2 [Member]
Foreign exchange gain (loss)
Foreign Currency Transaction Gain (Loss), before Tax
Furniture and fixtures
Furniture and Fixtures [Member]
Gain on sale of asset, net
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property
Gain on sale of short-term investments, net
Net gain on sale of short term investments
Gain on sale of short-term investments
Gain on Sale of Investments
General and administrative
General and Administrative Expense
General and administrative expenses
General and Administrative Expense [Member]
Identifiable Intangible Assets and Goodwill
Goodwill and Intangible Assets, Policy [Policy Text Block]
Goodwill impairment loss
Goodwill, Impairment Loss
Identifiable Intangible Assets
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]
Goodwill
Identifiable Intangible Assets and Goodwill
Goodwill and Intangible Assets Disclosure [Text Block]
Identifiable Intangible Assets and Goodwill
Impairment relating to its in-process research and development intangible assets
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Consolidated Statements of Comprehensive Loss
Loss before income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest
Income Statement Location [Axis]
Income Taxes
Income Tax Authority [Domain]
Income Tax Authority [Axis]
Income Taxes
Income Tax Disclosure [Text Block]
Income Statement Location [Domain]
Penalties and interest expense
Income Tax Examination, Penalties and Interest Expense
Benefit from income taxes
Benefit from income taxes
Income Tax Expense (Benefit)
Cash received for taxes
Income Taxes Paid, Net
Unrecognized tax benefits disclosures
Income Taxes
Income Tax Uncertainties [Abstract]
Income Taxes
Income Tax, Policy [Policy Text Block]
Asset retirement obligation
Accounts receivable
Increase (Decrease) in Accounts Receivable
Accounts payable
Increase (Decrease) in Accounts Payable
Accrued expenses and deferred rent
Deferred revenue
Increase (Decrease) in Deferred Revenue
Changes in operating assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Interest payable
Accrued compensation
Increase (Decrease) in Employee Related Liabilities
Income tax receivable
Increase (Decrease) in Income Taxes Receivable
Prepaid expenses and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Stockholders' Equity
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Effect of dilutive securities, Common stock warrant
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Effect of dilutive securities
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
Accrued interest payable
Interest Payable, Current
Interest expense
Interest Expense
Cash paid for interest
Interest Paid
IRS
Internal Revenue Service (IRS) [Member]
Investment income
Investment Income, Nonoperating
Rent expense charged to operations
Operating Leases, Rent Expense
Leasehold improvements
Leasehold Improvements [Member]
Commitments
Leases [Abstract]
Total current liabilities
Liabilities, Current
Total liabilities and shareholders' equity
Liabilities and Equity
Current liabilities:
Liabilities, Current [Abstract]
Total liabilities
Liabilities
Liabilities and shareholders' equity
Liabilities and Equity [Abstract]
License revenues
License and Services Revenue
License fees
Licenses Revenue
Maximum borrowing capacity of term loan
Line of Credit Facility, Maximum Borrowing Capacity
Loan and Security Agreement
Line of Credit [Member]
Total
Long-term Debt
2014
Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year
2015
Long-term Debt, Maturities, Repayments of Principal in Year Two
2016
Long-term Debt, Maturities, Repayments of Principal in Year Four
2016
Long-term Debt, Maturities, Repayments of Principal in Year Three
Current portion of long term debt
Long-term Debt, Current Maturities
Debt, long-term
Long-term debt
Long-term Debt, Excluding Current Maturities
2014
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months
Loss Contingency, Nature [Domain]
Loss Contingencies [Table]
Number of claims dismissed
Loss Contingency, Claims Settled and Dismissed, Number
Legal Proceedings
Loss Contingencies [Line Items]
Loss Contingency Nature [Axis]
Claims remaining
Loss Contingency, Pending Claims, Number
Major Types of Debt and Equity Securities [Axis]
Major Types of Debt and Equity Securities [Domain]
Future principal repayments of the Notes
Maturities of Long-term Debt [Abstract]
Maximum
Maximum [Member]
Minimum
Minimum [Member]
Percentage of ownership interest by legacy Insmed Incorporated shareholders (in hundredths)
Noncontrolling Interest, Ownership Percentage by Parent
Financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]
Operating activities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net loss
Net Income (Loss) Available to Common Stockholders, Basic
Net loss
Net cash used in operating activities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Numerator:
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Investing activities
Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]
Net loss
Net loss
Net loss
Net Income (Loss) Attributable to Parent
Recently Adopted Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Number of reportable segments
Number of Reportable Segments
Office equipment
Office Equipment [Member]
2019
Operating Leases, Future Minimum Payments, Due Thereafter
Future minimum rental payments under operating leases
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Operating expenses:
Operating Expenses [Abstract]
2017
Operating Leases, Future Minimum Payments, Due in Four Years
Total operating expenses
Operating Expenses
2018
Operating Leases, Future Minimum Payments, Due in Five Years
2016
Operating Leases, Future Minimum Payments, Due in Three Years
2014
Operating Leases, Future Minimum Payments Due, Next Twelve Months
2014 (remaining)
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year
Operating loss
Operating loss
Operating Income (Loss)
Operating Loss Carryforwards [Table]
NOL carryforwards
Operating Loss Carryforwards [Line Items]
2015
Operating Leases, Future Minimum Payments, Due in Two Years
Commitments
Operating Leased Assets [Line Items]
Total
Future minimum rental payments under leases
Operating Leases, Future Minimum Payments Due
Net operating loss carryforwards for income tax purposes
Operating Loss Carryforwards
The Company and Basis of Presentation
The Company and Basis of Presentation
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Unrealized loss on investments
Unrealized gain (loss) on investments
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax
Unrealized (loss) gain on short-term investments, net of taxes
Other assets
Other Assets
Unrealized gain (loss) on investment, net of taxes
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax
In-process research and development
Other Finite-Lived Intangible Assets, Gross
Other income, net
Other Nonoperating Income (Expense)
Other
Other Machinery and Equipment [Member]
Other revenue
Other Revenue, Net
Fair value of warrants in connection with debt
Other Significant Noncash Transaction, Consideration Given
Other accrued expenses
Other Accrued Liabilities, Current
Cash consideration for merger, net of cash acquired
Payments to Acquire Businesses, Net of Cash Acquired
Purchases of fixed assets
Payments to Acquire Property, Plant, and Equipment
Proceeds from issuance of common stock, issuance costs
Underwriter's discount and offering expenses
Payments of Stock Issuance Costs
Payment of debt issuance costs
Payments of Debt Issuance Costs
Purchases of short-term investments
Payments to Acquire Short-term Investments
Retirement Plan
Pension and Other Postretirement Benefits Disclosure [Text Block]
Plan Name [Domain]
Plan Name [Axis]
Preferred stock; $.01 par value; authorized shares 200,000,000; issued and outstanding shares, zero in 2011 and 9,174,589 in 2010
Preferred Stock
Preferred Stock [Member]
Prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current
Prior Period Reclassifications
Reclassification, Policy [Policy Text Block]
Proceeds from issuance of debt
Proceeds from Issuance of Debt
Borrowings of long-term debt, net of issuance costs
Proceeds from Debt, Net of Issuance Costs
Maturity of a certificate of deposit in 2013 and sales of short-term investments in 2012
Proceeds from Sale, Maturity and Collection of Short-term Investments
Other
Proceeds from (Payments for) Other Financing Activities
Maturity of a certificate of deposit
Proceeds from Maturities, Prepayments and Calls of Short-term Investments
Net proceeds from issuance of common stock
Net proceeds from the sale of shares
Proceeds from Issuance of Common Stock
Sales of short-term investments
Proceeds from Sale of Short-term Investments
Proceeds from exercise of stock options
Proceeds from Stock Options Exercised
Proceeds from sale of asset
Proceeds from Sale of Property, Plant, and Equipment
Estimated Useful Life
Estimated useful live of fixed assets
Property, Plant and Equipment, Useful Life
Fixed assets, gross
Property, Plant and Equipment, Gross
Fixed Assets, Net
Property, Plant and Equipment, Policy [Policy Text Block]
Fixed assets, net
Fixed assets, net
Property, Plant and Equipment, Net
Fixed Assets, net
Schedule of fixed assets
Property, Plant and Equipment [Table Text Block]
Property, Plant and Equipment, Type [Domain]
Property, Plant and Equipment, Type [Axis]
Fixed Assets, net
Property, Plant and Equipment Disclosure [Text Block]
Fixed Assets, Net
Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Quarterly Financial Data (Unaudited)
Quarterly Financial Information [Text Block]
Quarterly Financial Data (Unaudited)
Range [Axis]
Range [Domain]
Payments on capital lease obligations
Repayments of Long-term Capital Lease Obligations
Repayment of convertible notes
Repayments of Convertible Debt
Research and development
Research and Development Expense
Compensation earned under research funding agreements with CFFT
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned
Research and development expenses
Research and Development Expense [Member]
Research and Development
Research and Development Expense, Policy [Policy Text Block]
Restricted stock units
Restricted Stock Units (RSUs) [Member]
Restricted Stock (RS)
Restricted stock and restricted stock units
Restricted Stock [Member]
Accumulated Deficit
Retained Earnings [Member]
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Revenue Recognition
Revenue Recognition [Abstract]
Grant revenue
Revenue Recognition
Revenue Recognition, Policy [Policy Text Block]
Other expanded access program income, net
Cost recovery revenues from an Expanded Access Program
Revenue Other Manufactured Products
Other revenue
Total revenues
Revenues
Revenues
Royalty payable on approval of ARIKAYCE as commercialized drug
Royalty Guarantees, Commitments, Amount
Exercisable Options, Weighted Average Exercise Price (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price
Exercisable (in dollars)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Expected option term
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term
Outstanding Options, Weighted Average Exercise Price (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price
Purchase price per share as a percentage of fair market value of the shares on the purchase date
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Vested and expected to vest
Exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Options outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term
Previously reported
Scenario, Previously Reported [Member]
Scenario, Unspecified [Domain]
Schedule of Available-for-sale Securities [Table]
Assets and liabilities measured on recurring basis
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Summary of Company's stock option activity
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
Summary of Company's grant date fair value and assumptions used in determining fair value of stock options
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table]
Components of the Company's debt balances
Schedule of Debt [Table Text Block]
Future principal repayments of the Notes
Schedule of Maturities of Long-term Debt [Table Text Block]
Reconciliation between The Federal Statutory Tax Rate and Effective Tax Rate
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Deferred Tax Assets and Liabilities
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Accrued Expenses
Schedule of Accrued Liabilities [Table Text Block]
Future minimum rental payments required under operating leases
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Quarterly financial data (Unaudited)
Schedule of Quarterly Financial Information [Table Text Block]
Summary of Company's RSU activity
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]
Schedule of Available-for-sale Securities
Schedule of Available-for-sale Securities [Line Items]
Reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share
Schedule of Weighted Average Number of Shares [Table Text Block]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
Comprehensive (loss) income
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
Schedule of Operating Leased Assets [Table]
Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]
Summary of the aggregate stock-based compensation recorded in the Consolidated Statements of Comprehensive Loss
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Property, Plant and Equipment [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]
Schedule of Stock by Class [Table]
Summary of range of exercise prices and the number of stock options outstanding and exercisable
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]
Notes payable
Secured Debt
Segment Information
Segment Reporting, Policy [Policy Text Block]
Segment Information
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Geographical [Domain]
Series B Preferred Stock
Series B Preferred Stock [Member]
Requisite service period
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period
Number of RSUs
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Granted (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Granted (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Outstanding, beginning balance (in shares)
Outstanding, ending balance (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Number of additional shares authorized for current and future use
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Released (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Stock based compensation expense
Share-based Compensation
Annual sublimit for stock options, performance shares (including RSUs) and shares of restricted stock issued to a single employee
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee
Weighted Average Grant Price
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Stock Based Compensation disclosures
Stock Option disclosures
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding weighted average grant price (in dollars per share)
Outstanding weighted average grant price (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Stock-Based Compensation
Forfeited (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Shares price (in dollars per share)
Share Price
Exercised (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Exercisable (in dollars per share)
Dividend yield (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Fair value of RSUs that vested during the period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value
Released (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Exercisable (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Shares available for grant
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Total intrinsic value of stock options exercised during the period
Volatility (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Shares of common stock, maximum authorized for issuance
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Risk-free interest rate (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Fair value and assumptions used in determining fair value of stock options
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Weighted-average fair value of stock options granted (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Forfeited and expired (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Forfeited or expired (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Options outstanding (in dollars per share)
Options outstanding (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Stock-Based Compensation
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Options outstanding (in shares)
Options outstanding (in shares)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Vested and expected to vest (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Options outstanding (in dollars)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Exercise Price Range [Axis]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]
Number of Shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Equity Award [Domain]
Range of Exercise Prices lower range limit (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit
Vested and expected to vest (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Vested and expected to vest (in dollars)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Number of Options outstanding (in shares)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options
Number of Options exercisable (in shares)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options
Range of Exercise Prices upper range limit (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit
Balance (in shares)
Balance (in shares)
Shares, Outstanding
Short-term Investments
Short-term investments
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
State and Local Jurisdiction [Member]
New Jersey
Scenario [Axis]
Statement [Table]
Statement
Statement [Line Items]
Consolidated Statements of Stockholders' Equity
Geographical [Axis]
Consolidated Statements of Cash Flows
Equity Components [Axis]
Consolidated Balance Sheets
Stock Issued During Period, Shares, Period Increase (Decrease)
Issuance of common stock upon merger (in shares)
Issuance of common stock for vesting of RSUs
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures
Issuance of common stock for vesting of RSUs (in shares)
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures
Exercise of stock options
Stock Issued During Period, Value, Stock Options Exercised
Conversion of RSUs into common stock
Stock Issued During Period, Value, Conversion of Convertible Securities
Exercised (in shares)
Exercise of stock options (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Number of shares issued under underwritten public offering
Net proceeds from the issuance of common stock (in shares)
Stock Issued During Period, Shares, New Issues
Conversion of RSUs into common stock (in shares)
Stock Issued During Period, Shares, Conversion of Convertible Securities
Net proceeds from the issuance of common stock
Stock Issued During Period, Value, New Issues
Reverse stock split
Stockholders' Equity, Reverse Stock Split
Shareholders' equity:
Stockholders' Equity Attributable to Parent [Abstract]
Stockholders' Equity, Period Increase (Decrease)
Total shareholders' equity
Balance
Balance
Stockholders' Equity Attributable to Parent
Stockholders' Equity
Stockholders' Equity
Stockholders' Equity Note Disclosure [Text Block]
Reverse stock split
Stockholders' Equity Note, Stock Split, Conversion Ratio
Subsequent Events
Subsequent Events [Text Block]
Subsequent Events
Subsequent Event [Table]
Subsequent Events
Subsequent Event [Line Items]
Subsequent events
Subsequent Event [Member]
Subsequent Event Type [Domain]
Subsequent Event Type [Axis]
Supplemental disclosures of cash flow information:
Supplemental Cash Flow Information [Abstract]
Certificate of deposit
Time Deposits, at Carrying Value
Type of Arrangement and Non-arrangement Transactions [Axis]
Issuance fees paid to lender
Unamortized Debt Issuance Expense
Unrealized gain on investments
Unrealized Gain (Loss) on Investments
Unrecognized tax benefits
Uncertain tax positions
Unrecognized Tax Benefits
Unrecognized tax benefits, interest and penalties accrued
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Government Agencies Bonds
US Government Agencies Debt Securities [Member]
Increase in valuation allowance
Valuation Allowance, Deferred Tax Asset, Change in Amount
Warrant
Warrants to purchase common stock
Warrant [Member]
Warrant disclosures
Warrant Exercise
Warrants and Rights Note Disclosure [Abstract]
Fair value of warrant
Warrants Not Settleable in Cash, Fair Value Disclosure
Warrant to purchase common stock
Warrants and Rights Outstanding
Denominator:
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average common shares used in calculation of basic net loss per share:
Weighted Average Number of Shares Outstanding, Basic
Weighted average basic and diluted common shares outstanding (in shares)
Weighted Average Number of Shares Outstanding, Basic and Diluted
Weighted average common shares outstanding used in calculation of diluted net loss per share
Weighted Average Number of Shares Outstanding, Diluted